|
HERA stands for HERceptin®
Adjuvant Trial. HERA is co-ordinated
by BIG* and F. Hoffmann-La Roche Ltd. This important international
study aims to evaluate the effectiveness of adjuvant Herceptin®
in HER2-positive patients with primary breast cancer. Approximately
5,100 patients were enrolled from 480 sites in 39 countries.
The first patient was enrolled into the trial in December 2001.
Screening for entry into the HERA study was closed on the 21st
May 2004. Patients who have not yet been screened are no longer
able to enter the HERA study.
*Additional collaborative partners for the HERA
study include: collaborative groups affiliated with BIG, plus non-affiliated
collaborative groups, and independent sites.
This website has an area available to individuals interested in
HERA as well as a password-protected area for investigators participating
in HERA. If you would like to return to this site, please
this page.
| The patient information section is also available
in the following languages: |
 |
 |
 |
 |
|
